Ⅰ、Ⅱ期非小细胞肺癌术后辅助化疗疗效分析

Clinical observation of adjuvant chemotherapy after radical surgery for Stage Ⅰ、Ⅱ non-small cell lung cancer

目的评价Ⅰ、Ⅱ期非小细胞肺癌（NSCLC）切除术后辅助化疗的疗效。方法辅助化疗组102例于术后接受3～4周期的化疗，单纯手术组172例患者术后未行化疗。结果辅助化疗组术后复发、转移43例（42．2％），单纯手术组术后复发、转移85例（49．4％），两组比较差别无统计学意义（P〉0．05）。辅助化疗组和单纯手术组的5年生存率分别为45．1％（46／102）和42．4％（73／172），差别无统计学意义（P〉0．05）。结论对根治切除术后Ⅰ、Ⅱ期NSCLC患者不需常规进行辅助化疗。

Objective To evaluate the effect of adjuvant chemotherapy after radical surgery for stage Ⅰ, Ⅱ non-small cell lung cancer （NSCLC）. Methods We analysed clinical data in 274 cases of stage Ⅰ, Ⅱ NSCLC undergone resectional surgery. 102 patients received adjuvant chemotherapy after undergone radical surgery （adjuvant chemotherapy group）. 172 patients received surgery alone （surgery group）. Results The relapse or metastasis rate was 42.2% in the adjuvant chemotherapy group and 49.4% in the surgery group. There was no significant difference between two groups （P 〉 0.05）. The 5-year survival rate was 45.1% in the adjuvant chemotherapy group and 42.4% in the surgery group. There was no significant difference between two groups （P 〉 0.05） as well. Conclusion Adjuvant chemotherapy is not a recommended therapy methods for patients with stage Ⅰ、Ⅱ NSCLC.